reviewrheumatic diseasestreatmentmeloxicamобзорревматические заболеваниялечениемелоксикам1.Seibert K., Zhang Y. et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 1994; 91: 12013- 12014.2.Smith Y., Willis A. et al. Aspirin selectivity inhibits prostaglandin production in human platelets. Nature 1971; 231: 135-237.3.Насонов Е. Л., Цветкава Е. С. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер. арх. 1998; 5: 8-14.4.Needleman P., Isokson P. The discovery and function of COX-J. Rheumatol. 1997; 24 (suppl. 49): 6-8.5.Vane J. Towards a better aspirin. Nature 1994; 367: 215-216.6.Насонов Е. Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). ML; 2000.7.Сасасе L. Elevated serum СРК after drug injections. N. Engl.J. Med. 1972; 287: 309-310.8.Combe В., Velicitet P., Garzon N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm. Res. 2001; 50 (suppl. 1): S10-S16.9.Auvinet В., Ziler R., Appelboom T. et al. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin. Ther. 1995; 17 (6): 78-90.10.Stei P., Kruss В., Wiegleb J. et al. Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Br. J. Rheumatol. 1996; 35 (1): 44-50.11.Narjes H., Turck D., Busch V. et el. Pharmacokinetics and tolerability of meloxicam after in administration. Br. J. Clin. Pharmacol. 1996; 41: 135-139.12.Colberg K., Netting M. et al. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr. Med. Res. Opin. 1996; 13 (7): 363-377.13.Grozlan P., Bernhardt M., Velicitat P. et el. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br. i. Rheumatol. 1996; 35 (I): 51 - 55.14.Bosch H., Sigmund R., Hettich M. Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: comparison with intramuscular and oral piroxicam. Curr. Med. Res. Opin. 1997; 14 (1): 29-38.15.Euller-Ziegler L., Velicitat P., Bluhmki E. et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm. Res. 2001; 50 (suppl. 1): S5-S9.